Category Archives: Cell Medicine

TORRANCE, Calif., May 29, 2012 /PRNewswire/ --Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions. "We are very pleased with the EMA's recognition of our L-glutamine therapy as an orphan medicinal product for the treatment of sickle cell disease in Europe," said Yutaka Niihara, M.D., MPH, founder and CEO of Emmaus. "This designation is an important milestone in our effort to make this treatment available to millions of patients around the world who currently have very few therapies available to them." Emmaus Medical has already received orphan drug and fast track designations from the U.S. Food and Drug Administration (FDA) for its patented L-glutamine drug, and is seeking FDA approval for L-glutamine as a treatment of sickle cell disease.The drug was originally developed … Continue reading →

28 May 2012 Last updated at 09:14 ET A 54m cutting-edge stem cell research centre in Edinburgh has been officially opened by the Princess Royal. The Royal opened the Scottish Centre for Regenerative Medicine as well as the 24m bio-incubator facility, Nine, in the Edinburgh BioQuarter. Research into conditions such as multiple sclerosis and heart and liver disease will benefit from the new facilities in Little France. The Princess Royal unveiled plaques at the centres. Edinburgh University's Scottish Centre for Regenerative Medicine is the first large-scale, purpose-built facility of its kind and provides accommodation for up to 250 stem cell scientists. The centre, funded by Edinburgh University, Scottish Enterprise, the Medical Research Council (MRC) and the British Heart Foundation through its Mending Broken Hearts Appeal, is being opened by the Princess Royal in her role as Chancellor of Edinburgh University. It includes the most up-to-date facilities in the UK, which meet the highest guidelines, to manufacture stem cell lines that could be used for patient therapies. Nine, which has been jointly funded by Scottish Enterprise and the UK government's department for business, innovation and skills, has 85,000 sq ft of laboratory and office space for both established biotechnology companies and … Continue reading →

More Topics: Choose a Sector Accounting Firms Advertising/Media/Communications Capital CEO/Board General Business Health/Biotech Internet/Technology Investment Firms Law Firms Mergers & Acquisitions Money Managers People Private Companies Public Companies Venture Capital Posted May 29, 2012 Philip A. Lowry Highly Recognized Bone Marrow Stem Cell Transplant Specialist Added to Existing Member Expertise in Maternal Fetal Medicine, Cardiology, and Pathology CLEARWATER, FL -- Biostem U.S., Corporation, (OTCQB: HAIR) (PINKSHEETS: HAIR) a stem cell regenerative medicine sciences company, announced that Philip A. Lowry, MD, has been appointed as the Chairman of its Scientific and Medical Board of Advisors (SAMBA). According to Biostem CEO, Dwight Brunoehler, "As Chairman, Dr. Lowry will work with a team drawn from a cross-section of medical specialties. His combination of research, academic and community practice experience make him the perfect individual to coordinate and lead the outstanding group of physicians that makes up our SAMBA. As a group, The SAMBA will guide the company to maintain the highest ethical standards in every effort, while seeking and developing new cutting edge technology based on stem cell use. I am privileged to work with Dr. Lowry, once again." Dr. Lowry stated, "Dwight is an innovative businessman with an eye on cutting-edge stem … Continue reading →

SUNRISE, Fla., May 29, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT.OB - News) announced today that it will offer another laboratory training course in partnership with the Ageless Regenerative Institute, an organization dedicated to the standardization of cell regenerative medicine, on Saturday/Sunday June 23-24, 2012. Attendees will participate in hands on, in depth training in laboratory practices in stem cell science at Bioheart, Inc.'s corporate headquarters and clean room in Sunrise, Florida. The course was designed for Laboratory technicians, Students, Physicians and Physician Assistants. "Attendees will graduate from this one-of-a-kind course with an extensive understanding of stem cell science laboratory practices," said Kristin Comella, Chief Scientific Officer, Bioheart, Inc. "Previous attendees described the course as incredibly well orchestrated providing comprehensive know how for laboratory start up." An emerging field with tremendous opportunities, adult stem cell research has been shown to regenerate and repair injured or diseased structures via the release of bioactive tissue growth factors and cytokines. This is the second time that The Ageless Regenerative Institute has partnered with Bioheart, Inc. to provide hands-on training in a stem cell laboratory. This course provides instruction regarding how to grow stem cells and perform quality control testing in an actual cGMP … Continue reading →

EDINBURGH, Scotland, May 29, 2012 /PRNewswire/ -- Research into conditions such as multiple sclerosis and heart and liver disease will benefit from multi-million dollar stem cell research and life sciences facilities opened yesterday by HRH, the Princess Royal. The Princess Royal is to unveil plaques this afternoon at the $85 million Scottish Centre for Regenerative Medicine (SCRM) and $38 million bio-incubator facility, Nine, in Edinburgh. The University of Edinburgh's Scottish Centre for Regenerative Medicine will carry out cutting-edge stem cell research to help find therapies for patients with conditions such as multiple sclerosis, Parkinson's disease, motor neurone disease, and heart and liver diseases. The centre is the first large-scale, purpose-built facility of its kind and provides accommodation for up to 250 stem cell scientists. The centre, funded by the University of Edinburgh, Scottish Enterprise, the Medical Research Council (MRC) and the British Heart Foundation through its Mending Broken Hearts Appeal, was opened by the Princess Royal in her role as Chancellor of the University. It includes the most up-to-date facilities in the UK, which meet the highest guidelines, to manufacture stem cell lines that could be used for patient therapies. Nine, which has been jointly funded by Scottish Enterprise and … Continue reading →

CLEARWATER, FL--(Marketwire -05/29/12)- Biostem U.S., Corporation, (HAIR.PK) (HAIR.PK) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, today announced that Philip A. Lowry, MD, has been appointed as the Chairman of its Scientific and Medical Board of Advisors (SAMBA). According to Biostem CEO, Dwight Brunoehler, "As Chairman, Dr. Lowry will work with a team drawn from a cross-section of medical specialties. His combination of research, academic and community practice experience make him the perfect individual to coordinate and lead the outstanding group of physicians that makes up our SAMBA. As a group, The SAMBA will guide the company to maintain the highest ethical standards in every effort, while seeking and developing new cutting edge technology based on stem cell use. I am privileged to work with Dr. Lowry, once again." Dr. Lowry stated, "Dwight is an innovative businessman with an eye on cutting-edge stem cell technology. His history in the industry speaks for itself. I like the plan at Biostem and look forward to working with everyone involved." Dr. Philip A. Lowry received his undergraduate degree from Harvard College before going on to the Yale University School of Medicine. His completed his internal … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/xf5djc/plasma_medicine_a) has announced the addition of the "Plasma Medicine. Applications of Low-Temperature Gas Plasmas in Medicine and Biology" report to their offering. The introduction of low temperature plasma technology to medical research and to the healthcare arena in general is set to revolutionise the way we cure diseases. This innovative medium offers a valid and advantageous replacement of traditional chemical-based medications. Its application in the inactivation of pathogens in particular, avoids the recurrent problem of drug resistant microorganisms. This is the first book dedicated exclusively to the emerging interdisciplinary field of plasma medicine. The opening chapters discuss plasmas and plasma chemistry, the fundamentals of non-equilibrium plasmas and cell biology. The rest of the book is dedicated to current applications, illustrating a plasma-based approach to wound healing, electrosurgery, cancer treatment and even dentistry. The text provides a clear and integrated introduction to plasma technology and has been devised to answer the needs of researchers from different communities. It will appeal to graduate students and physicists, engineers, biologists, medical doctors and biochemists. Key Topics Covered: Foreword Part I. Introduction to Non-equilibrium Plasma, Cell Biology, and Contamination: 1. Introduction 2. Fundamentals of non-equilibrium plasmas 3. Non-equilibrium plasma sources … Continue reading →

Public release date: 25-May-2012 [ | E-mail | Share ] Contact: Scott LaFee slafee@ucsd.edu 619-543-6163 University of California - San Diego Five scientists from the University of California, San Diego and its School of Medicine have been awarded almost $12 million in new grants from the California Institute for Regenerative Medicine (CIRM) to conduct stem cell-based research into regenerating spinal cord injuries, repairing gene mutations that cause amyotrophic lateral sclerosis and finding new drugs to treat heart failure and Alzheimer's disease. The awards mark the third round of funding in CIRM's Early Translational Awards program, which supports projects that are in the initial stages of identifying drugs or cell types that could become disease therapies. More than $69 million in awards were announced yesterday, including funding for first-ever collaboratively funded research projects with China and the federal government of Australia. "With these new awards, the agency now has 52 projects in 33 diseases at varying stages of working toward clinical trials," said Jonathan Thomas, JD, PhD and CIRM governing board chair. "Californians should take pride in being at the center of this worldwide research leading toward new cures. These projects represent the best of California stem cell science and the … Continue reading →

Five UC San Diego scientists have received almost $12 million combined from the California Institute for Regenerative Medicine to pay for stem cell-based research, the university announced today. A team led by Lawrence Goldstein, of the Department of Cellular and Molecular Medicine and director of the UC San Diego Stem Cell Program, was given $1.8 million to continue looking for new methods to find and test possible medications for Alzheimer's disease, according to UCSD. They use reprogrammed stem cells in their work. Dr. Mark Tuszynski, professor of neurosciences and director of the Center for Neural Repair, received $4.6 million to develop more potent stem cell-based treatments for spinal cord injuries. Gene Yeo, assistant professor in the Department of Cellular and Molecular Medicine, was awarded $1.6 million to continue research into treatments for amyotrophic lateral sclerosis. His research hopes to take advantage of recent discoveries about ALS, or Lou Gehrig's disease, which center on mutations in RNA-binding proteins that cause dysfunction and death in neurons. Dr. Eric David Adler, an associate clinical professor of medicine and cardiologist, was granted $1.7 million to screen potential drugs for Danon disease, a type of inherited heart failure that frequently kills patients by their 20s. … Continue reading →

DUARTE, Calif.--(BUSINESS WIRE)-- City of Hope was granted a $5,217,004 early translational research award by the California Institute for Regenerative Medicine (CIRM) to support the development of a T cell-based immunotherapy that re-directs a patients own immune response against glioma stem cells. City of Hope has been awarded more than $49.7 million in grant support from CIRM since awards were first announced in 2006. City of Hope is a pioneer in T cell immunotherapy research, helping to develop genetically modified T cells as a treatment for cancer. This strategy, termed adoptive T cell therapy, focuses on redirecting a patients immune system to specifically target tumor cells, and has the potential to become a promising new approach for treatment of cancer. In this research, we are genetically engineering a central memory T cell that targets proteins expressed by glioma stem cells, said Stephen J. Forman, M.D., Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation and director of the T Cell Immunotherapy Research Laboratory. Central memory T cells have the potential to establish a persistent, lifelong immunity to help prevent brain tumors from recurring. The American Cancer Society estimates that more than 22,000 people in the U.S. will … Continue reading →